Li F, Li H, Luo R, Pei JB, Yu XY. Lyophilized recombinant human brain natriuretic peptide for chronic heart failure: Effects on cardiac function and inflammation. World J Clin Cases 2023; 11(26): 6066-6072 [PMID: 37731575 DOI: 10.12998/wjcc.v11.i26.6066]
Corresponding Author of This Article
Feng Li, Associate Chief Physician, Master's Student, Department of Cardiovascular Internal Medicine, People's Hospital of Jieshou, No. 399 Renmin East Road, Jieshou 236500, Anhui Province, China. lff753159789@163.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Sep 16, 2023; 11(26): 6066-6072 Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6066
Lyophilized recombinant human brain natriuretic peptide for chronic heart failure: Effects on cardiac function and inflammation
Feng Li, Hao Li, Rong Luo, Jia-Bao Pei, Xue-Ying Yu
Feng Li, Hao Li, Rong Luo, Jia-Bao Pei, Xue-Ying Yu, Department of Cardiovascular Internal Medicine, People's Hospital of Jieshou, Jieshou 236500, Anhui Province, China
Author contributions: Li F and Li H contributed equally to this work; Li F, Li H, Luo R, Pei JB, and Yu XY designed the research study; Li F, Li H, Pei JB, and Luo R performed the research; Yu XY and Li F contributed new reagents and analytic tools; Li F, Li H and Pei JB analyzed the data and wrote the manuscript; and all authors have read and approve the final manuscript.
Institutional review board statement: The study was reviewed and approved by the People's Hospital of Jieshou Institutional Review Board.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors have no conflicts of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Feng Li, Associate Chief Physician, Master's Student, Department of Cardiovascular Internal Medicine, People's Hospital of Jieshou, No. 399 Renmin East Road, Jieshou 236500, Anhui Province, China. lff753159789@163.com
Received: April 24, 2023 Peer-review started: April 24, 2023 First decision: May 8, 2023 Revised: May 20, 2023 Accepted: August 3, 2023 Article in press: August 3, 2023 Published online: September 16, 2023 Processing time: 137 Days and 1.5 Hours
Abstract
BACKGROUND
Chronic heart failure (CHF) is a serious and prevalent condition characterized by impaired cardiac function and inflammation. Standard therapy for CHF has limitations, prompting the exploration of alternative treatments. Recombinant human brain natriuretic peptide (BNP) has emerged as a potential therapy, with evidence suggesting that it can improve cardiac function and reduce inflammation in patients with CHF. However, further research is required to determine the efficacy and safety of lyophilized recombinant human BNP in CHF patients and its impact on microinflammatory status. This study aimed to investigate the effects of lyophilized recombinant human BNP therapy on CHF patients’ cardiac function and microinflammatory status.
AIM
To investigate the effects of freeze-dried recombinant human BNP therapy on cardiac function and microinflammatory status in patients with CHF.
METHODS
In total, 102 CHF patients admitted to our hospital from January 2021 to January 2022 were randomly assigned to control and observation groups (n = 51 patients/group). The control patients were treated with standard HF therapy for 3 d, whereas the observational patients were injected with the recombinant human BNP for 3 d. Clinical efficacy, inflammatory factor levels, myocardial damage, cardiac function before and after the treatment, and adverse reactions during treatment were compared between the two groups.
RESULTS
The overall clinical efficacy was higher in the observation group than in the control group. Compared with baseline, serum hypersensitive C-reactive protein, N-terminal proBNP, and troponin I level, and physical, emotional, social, and economic scores were lower in both groups after treatment, with greater reductions in levels and scores noted in the observation group than in the control group. The overall incidence of adverse reactions in the observation group was not significantly different compared with that in the control group (P > 0.05).
CONCLUSION
Freeze-dried recombinant human BNP therapy can improve heart function and enhance microinflammatory status, thereby improving overall quality of life without any obvious side effects. This therapy is safe and reliable.
Core Tip: Lyophilized recombinant human brain natriuretic peptide therapy can improve heart function and reduce microinflammation in patients with chronic heart failure, which signifies its potential as a safe and effective treatment option.
